18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy

Study Overview
=================
Brief Summary
-----------------
Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung cancer treated by immunotherapy.

Detailed Description
-----------------
Study EFS in patients with melanoma or NSCLC treated by immunotherapy (anti CTLA4 or anti PDL1) and performed18FDG PET Multicentric retrospective study

Official Title
-----------------
18FluoroDeoxyGlucose-Positron Emission Tomography (PET) in Patients With Melanoma or Non Small Cell Lung Cancer Treated With Immunotherapy

Conditions
-----------------
Melanoma, NSCLC, Positron-Emission Tomography, Immunotherapy, 18F-FDG

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients treated for melanoma or NSCLC with immunotherapy (anti CTLA4 or antiPDL1) patients treated in Brest, Morlaix, Landerneau hospital patients performed FDG PET no opposition to study Exclusion Criteria: age under 18 years old refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measure of progression free survival (obtained by the delay between the date of initiation of immunotherapy until the date of first documented progression disease in patients with melanoma or NSCLC treated by immunotherapy | From date of initiation of treatment until the date of first documented progression disease according to different criteria in interim PET/CT 1. 18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria. | up to 50 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measure of overall survival (obtained by the delay between the date of initiation of immunotherapy until the date of death related to disease in patients with melanoma or NSCLC treated by immunotherapy | From date of initiation of treatment until the date of death related to disease according to different criteria in interim PET/CT 1. 18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria. | up to 50 months | 
| Study different criteria (RECIST, iRECIST, PERCIST and PECRIT) to predict PFS or OS | Interpretation according to 4 criteria to predict response to immunotherapy | up to 50 months | 
| study the potential correlation between PET data and clinicobiological data | correlation between adverse events (AE) due to immunotherapy described on PET data and AE detected on clinicobiological data | up to 50 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
melanoma, NSCLC, FDG, PET, immunotherapy